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We have recently analyzed the expression 
of the chemokine CCL5 and its receptors 
in human breast cancer samples as well as 
in the normal breast epithelium.1 We found 
that CCL5/CCR5 signaling is preferen-
tially active in basal and ERBB2+ disease 
subtypes. Analyzing a combined microar-
ray database including 2,254 samples from 
27 independent studies,2 we demonstrated 
that 58% or more patients affected by the 
basal and ERBB2+ subtype of breast cancer 
significantly overexpress both CCL5 and 
CCR5. In contrast, when a similar analy-
sis was performed in non-neoplastic breast 
samples, no correlation between CCL5 and 
CCR5 expression levels was found, indi-
cating that CCL5/CCR5 signaling may be 
preferentially activated during the devel-
opment of specific breast cancer subtypes. 
In line with this notion, the invasiveness 
of human MCF-10A breast cancer cells 
transduced with Neu-T, H-RAS or c-SRC 
oncogenes increased in response to CCL5, 
suggesting that CCL5/CCR5 signaling is 
activated by oncogenic events to promote 
an aggressive phenotype.
Patients affected by basal breast car-
cinomas are at increased risk of metas-
tasis and exhibit poor survival rates.3,4 
Thus, we evaluated the importance of 
the CCL5/CCR5 axis in invasion and 
metastasis. By using human breast can-
cer cell lines exhibiting a basal phenotype 
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and  molecular signature, we demon-
strated that the increased expression of 
CCR5 we had observed in tissue micro-
array might be caused by the existence 
of a CCR5+ cell population. Phenotypic 
analyses demonstrated that a small frac-
tion of cells within breast cancer cell lines 
express CCR5 and functional analyses 
showed that such CCR5+ cells respond 
to CCL5. Furthermore, basal breast can-
cer cells expressing CCR5 display an 
increased invasiveness and metastatic 
potential. Metastatic tumors generated by 
the intravenous injection of breast cancer 
MDA-MB-231 cells transduced with a 
lentiviral vector coding for luciferase fused 
to an enhanced variant of the green-flu-
orescent protein (Luc2-eGFP) displayed 
an 8-fold increase in the proportion of 
CCR5+ cells as compared with the same 
cell line maintained in vitro. This indi-
cates either that the invasive population is 
enriched in CCR5+ cells or that the micro-
enviroment at metastatic sites promotes a 
CCR5+ phenotype. In an additional series 
of experiments, we showed that CCR5+ 
cells isolated from basal breast cancer 
cell lines are approximately 40-fold more 
invasive in vitro than their CCR5- coun-
terparts, indicating that CCR5 expression 
correlates with a pro-invasive phenotype.
The importance of CCR5 in HIV 
infection led to the development of 
drugs that specifically target this recep-
tor. CCR5 antagonists, which were origi-
nally developed to prevent the interaction 
between CCR5 and the gp120 glycopro-
tein of HIV-1, can efficiently block CCR5 
activity at nanomolar concentrations.5,6 
We therefore examined the possibility that 
CCR5 inhibition may reduce the invasive 
and metastatic potential of breast cancer 
cells. The CCR5 antagonists Maraviroc 
and Vicriviroc (both employed at a con-
centration of 100 nM) impaired CCL5-
stimulated cytoplasmic calcium waves and 
reduced the invasiveness of basal breast 
cancer cells. We also evaluated Maraviroc 
effects in vivo, using a mouse model of 
metastatic breast cancer. The intrave-
nous injection of Luc2-eGFP-expressing 
MDA-MB-231 breast cancer cells indeed 
generates pulmonary metastasis that can 
be easily followed by bioluminescence 
imaging. In this setting, the administra-
tion of Maraviroc at the clinically relevant 
dose of 8 mg/kg (twice daily) efficiently 
reduced pulmonary tumor burden 
(Fig. 1). Histological analyses performed 
on animals treated with Maraviroc for five 
weeks confirmed a significant reduction 
of both the number and the size of pul-
monary metastases (Fig. 1). Only 50% of 
Maraviroc-treated mice exhibited detect-
able neoplastic lesions and mean tumor 
size was reduced by > 65% as compared 
recently, we have shown that the CCL5/CCr5 axis is active in patients affected by an aggressive basal subtype of breast 
cancer. using preclinical models, we have demonstrated that CCr5 promotes breast cancer invasiveness and metastatic 
potential, while CCr5 inhibition abrogates them. thus, CCr5 antagonists may constitute an alternative therapeutic 
approach for patients affected by metastatic basal breast cancer.
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growth of pre-established pulmonary 
metastases in vivo. Taken together, these 
results indicate that CCR5 activation does 
not promote the proliferation of basal 
breast cancer cells and that the anti-meta-
static effect of CCR5 antagonists does not 
stem from effects on tumor growth.
To further clarify the mechanisms by 
which CCR5 promotes metastasis, we 
evaluated the effects of Maraviroc on the 
homing of breast cancer cells to the lungs. 
Of note, Maraviroc reduced the number of 
cancer cells that could be detected in the 
metastatic breast cancer did not allow us 
to understand whether CCR5 influences 
cell proliferation or tissue colonization. 
We therefore analyzed the role of CCR5 
on tumor cell proliferation by three dif-
ferent strategies. We observed that (1) 
Maraviroc as well as Vicriviroc do not 
affect the viability and proliferative poten-
tial of MDA-MB-231 cells in vitro; (2) 
CCR5 overexpressing cells display the 
same proliferation rate as cells transfected 
with an empty vector; and (3) the admin-
istration of Maraviroc does not alter the 
with vehicle-treated mice. These results 
demonstrate (1) that basal breast can-
cer cells are sensitive to pharmacological 
CCR5 inhibition, and (2) that the pro-
invasive and pro-metastatic activities of 
CCR5 can be abrogated by using specific 
antagonists.
CCR5 has also been shown to alter the 
proliferation of luminal breast cancer7,8 
and prostate cancer cell lines.9 However, 
the impact of CCR5 on the prolifera-
tion of basal cancer cells is controversial. 
The results obtained with our model of 
Figure 1. the CCr5 antagonist Maraviroc inhibits lung metastases in vivo. MDA-MB-231 cells expressing luciferase fused to an enhanced variant of the 
green-fluorescent protein (Luc2-eGFP) were injected into the tail vein of NOD/sCID mice and the bioluminescent signal was quantified weekly in vivo. 
representative images of mice receiving vehicle or 8 mg/Kg Maraviroc (every 12 h) are shown in (A) Quantitative data on bioluminescence imaging 
(means ± seM, n = 6) are reported in panel (B) (control mice = red line; treated mice = blue line). statistical comparisons (*p = 0.048) were by means 
of student’s t-tests coupled to welch’s correction for heterogeneous variances. (C) the presence of pulmonary tumors and the differences between 
experimental groups were corroborated by ex vivo imaging (left panels) and India ink staining (right panels).
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phenotype of basal breast cancer, both in 
clinical samples and in cell lines. We were 
also the first to report the anti-metastatic 
effects of a CCR5 antagonist that has 
already been licensed by FDA for use in 
humans.
Our data suggest that CCR5 antago-
nists may be used to reduce the risk of 
metastasis in patients bearing basal breast 
cancer. Given the aggressive course of the 
disease and the lack of targeted thera-
pies, the use of CCR5 antagonists as an 
lungs of mice 24 h after intravenous injec-
tion by 40%. Our results are in agreement 
with previous findings demonstrating that 
the CCL5/CCR5 signaling axis plays a 
crucial role in the metastatic cascade as it 
is involved in cancer cell extravasation.10 
Blocking the homing of cancer cells to 
metastatic sites is a highly desirable feature 
for a bona fide anti-metastatic drug.
Our recent paper1 demonstrates for the 
first time that the expression of CCR5 
and CCL5 correlates with a metastatic 
adjuvant therapy may constitute a major 
improvement in the clinical management 
of basal breast cancer patients.
Disclosure of Potential Conflicts of Interest
R.G.P. holds minor (< $10,000) own-
ership interests in, and serves as CSO/
Founder of the biopharmaceutical compa-
nies ProstaGene, LLC and AAA Phoenix, 
Inc. R.G.P. additionally holds ownership 
interests (value unknown) for several sub-
mitted patent applications.
References
1. Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell 
TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks 
metastasis of basal breast cancer cells. Cancer Res 
2012; 72:3839-50; PMID:22637726; http://dx.doi.
org/10.1158/0008-5472.CAN-11-3917
2. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, 
Knudsen KE, et al. RB-pathway disruption in breast 
cancer: differential association with disease subtypes, 
disease-specific prognosis and therapeutic response. 
Cell Cycle 2010; 9:4153-63; PMID:20948315; http://
dx.doi.org/10.4161/cc.9.20.13454
3. Meyers MO, Klauber-Demore N, Ollila DW, Amos 
KD, Moore DT, Drobish AA, et al. Impact of breast 
cancer molecular subtypes on locoregional recurrence 
in patients treated with neoadjuvant chemotherapy 
for locally advanced breast cancer. Ann Surg Oncol 
2011; 18:2851-7; PMID:21442348; http://dx.doi.
org/10.1245/s10434-011-1665-8
4. Kennecke H, Yerushalmi R, Woods R, Cheang MC, 
Voduc D, Speers CH, et al. Metastatic behavior of 
breast cancer subtypes. J Clin Oncol 2010; 28:3271-
7; PMID:20498394; http://dx.doi.org/10.1200/
JCO.2009.25.9820
5. Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, 
Gross R, et al. Three-year safety and efficacy of vicrivi-
roc, a CCR5 antagonist, in HIV-1-infected treatment-
experienced patients. J Acquir Immune Defic Syndr 
2010; 54:470-6; PMID:20672447; http://dx.doi.
org/10.1097/QAI.0b013e3181e2cba0
6. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, 
Macartney M, et al. Maraviroc (UK-427,857), a 
potent, orally bioavailable, and selective small-mol-
ecule inhibitor of chemokine receptor CCR5 with 
broad-spectrum anti-human immunodeficiency 
virus type 1 activity. Antimicrob Agents Chemother 
2005; 49:4721-32; PMID:16251317; http://dx.doi.
org/10.1128/AAC.49.11.4721-4732.2005
7. Mañes S, Mira E, Colomer R, Montero S, Real LM, 
Gómez-Moutón C, et al. CCR5 expression influ-
ences the progression of human breast cancer in a 
p53-dependent manner. J Exp Med 2003; 198:1381-
9; PMID:14597737; http://dx.doi.org/10.1084/
jem.20030580
8. Murooka TT, Rahbar R, Fish EN. CCL5 promotes pro-
liferation of MCF-7 cells through mTOR-dependent 
mRNA translation. Biochem Biophys Res Commun 
2009; 387:381-6; PMID:19607806; http://dx.doi.
org/10.1016/j.bbrc.2009.07.035
9. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. 
Expression of CCL5 (RANTES) and CCR5 in prostate 
cancer. Prostate 2006; 66:124-34; PMID:16161154; 
http://dx.doi.org/10.1002/pros.20306
10. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks 
MW, Bell GW, et al. Mesenchymal stem cells with-
in tumour stroma promote breast cancer metastasis. 
Nature 2007; 449:557-63; PMID:17914389; http://
dx.doi.org/10.1038/nature06188
